Polaris Market Research today announced findings from its latest report, projecting the global Diverticulitis Disease Market to grow from USD 1.56 billion in 2022 to USD 3.86 billion by 2032, at a CAGR of 8.91% over 2023–2032. The report profiles 17 leading companies across four segmentation dimensions: type, treatment, end-user and region.

Analyst Commentary on Diverticulitis Disease Growth

“An ageing population, rising obesity and sedentary lifestyles are expanding the patient pool, while evolving guidelines are reshaping how the condition is treated, and both are driving market growth,” said a Polaris Market Research analyst. “Manufacturers and providers aligned with outpatient care and selective antibiotic use are best placed to capture the opportunity through 2032.”

Diverticulitis Disease Market Statistics at a Glance

• 2022 Market Size: USD 1.56 billion
• 2032 Projected Size: USD 3.86 billion
• CAGR (2023–2032): 8.91%
• Largest Region (2021): North America

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: An ageing population, rising obesity, sedentary lifestyles and growth in gastrointestinal disease are the primary forces behind the industry's expansion, alongside new management guidelines for uncomplicated diverticulitis. Diverticulosis affects about 10% of adults over 40 and 50% of people over 60 in Western societies, and the WHO estimates that 1.4 billion people will be aged 60 or older by 2030, up from 1 billion in 2020. Research supports this shift: trials reported in recent years found antibiotics did not improve outcomes in simple acute diverticulitis among hospitalised patients. Guidance from bodies such as the American Society of Colon and Rectal Surgeons now supports treating selected uncomplicated cases without antibiotics, and outpatient management has proven effective. New product launches are also seen as a key lever for widening opportunities worldwide.

Major Companies Covered: Pfizer, Teva Pharmaceutical Industries, Abbott Laboratories, GSK plc, Bayer HealthCare Pharmaceuticals, Roche Holding AG, Novartis AG and Baxter International, among others.

Segments Covered: By Type (Uncomplicated, Complicated), By Treatment (Medications, Surgery, Supportive Care, Antibiotics, Dietary Supplements, IV Fluids), By End-User (Specialty Centres, Hospitals, Research Centres), and By Region.

Segment Highlights: Uncomplicated diverticulitis is predicted to dominate by type; acute simple diverticulitis affects roughly 4–5% of people with diverticulosis, and recurrence is reported in 13.3–23.4% of patients. Medications lead by treatment, with antibiotic regimens such as oral ciprofloxacin with metronidazole, or amoxicillin/clavulanate, in common outpatient use. Hospitals contributed the largest end-user revenue share in 2022, since they can guide test selection and admit higher-risk patients, such as those unable to tolerate oral intake, with persistent vomiting, peritonitis symptoms, weakened immunity or advanced age. Early in the pandemic, deferred care led to more emergency surgery and longer stays, underscoring the need for timely treatment.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/diverticulitis-disease-market 

Recent Developments in Diverticulitis Care

• July 2026: The American College of Gastroenterology published a new colonic diverticulitis guideline suggesting against routine antibiotics for low-risk acute uncomplicated cases and recommending colonoscopy after recovery from complicated diverticulitis.
• January 2022: The American College of Physicians released two clinical guidelines on diagnosing and treating diverticulitis, noting that most patients with simple disease can be treated as outpatients and some without initial antibiotics.

Regional Snapshot: North America Leads

North America generated the majority of revenue in 2021, supported by a rising senior population, higher rates of obesity and smoking, demand for technologically improved treatments and greater health awareness. The U.S. adult obesity rate stands at 42.4%, and diverticulitis is estimated to account for about 200,000 inpatient hospital stays and 371,000 emergency department visits a year, at a cost of USD 2.1–2.6 billion, while roughly 71,000 admissions a year are linked to diverticular hemorrhage. Europe, Asia Pacific, Latin America and the Middle East & Africa are also covered, with country-level analysis for the U.S., Germany, China, India, Brazil, Saudi Arabia and others.

Why It Matters for Stakeholders Tracking the Market Forecast to 2032

For stakeholders researching top companies and Diverticulitis Disease market share, the underlying report benchmarks company positioning, segment-level forecasts by type, treatment and end-user, and regional demand to support sourcing, partnership and investment decisions through 2032. It also weighs headwinds such as the high cost of treatment, and the lingering effect of pandemic-era treatment delays on patient outcomes. Rising obesity and the growing use of oral drugs are tracked as demand signals, giving manufacturers, hospital systems and investors a clearer view of where treatment spending is heading.

More Trending Latest Reports By Polaris Market Research:

Gypsum Board Market

Guillain-Barre Syndrome Market

Camping Furniture Market

Prostaglandin Analogs Market

Guillain-Barre Syndrome Market

Agricultural Robots Market

Research Department Explosives Market

Connected Worker Technologies to Play a Vital Role in Boosting Industrial Transformation

Silicone Market